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Abstract: Cigarette smoking is a risk factor for the development of peripheral artery disease (PAD),
although the proatherosclerotic mediators of cigarette smoking are not entirely known. We explored
whether circulating microRNAs (miRNAs) are dysregulated in cigarette smokers and associated
with the presence of PAD. Ninety-four participants were recruited, including 58 individuals without
and 36 with PAD, 51 never smokers, 28 prior smokers, and 15 active smokers. The relative expres-
sion of six circulating miRNAs with distinct biological roles (miR-21, miR-27b, miR-29a, miR-126,
miR-146, and miR-218) was assessed. Cigarette smoking was associated with the presence of PAD
in multivariate analysis. Active smokers, but not prior smokers, presented miR-27b downregu-
lation and higher leukocyte, neutrophil, and lymphocyte counts; miR-27b expression levels were
independently associated with active smoking. Considering the metabolic and/or inflammatory ab-
normalities induced by cigarette smoking, miR-27b was independently associated with the presence
of PAD and downregulated in patients with more extensive PAD. In conclusion, the atheroprotective
miR-27b was downregulated in active smokers, but not in prior smokers, and miR-27b expression
was independently associated with the presence of PAD. These unreported data suggest that the
proatherogenic properties of cigarette smoking are mediated by a downregulation of miR-27b, which
may be attenuated by smoking cessation.
Keywords: atherosclerosis; cigarette smoking; miR-27b; peripheral artery disease
1. Introduction
Cigarette smoking is a major health hazard, being accountable for substantial car-
diovascular morbidity and mortality worldwide due to its proatherogenic effects [1].
Cigarette smoking increases the risk of atherosclerosis development by several fold and is
a more influential risk factor for peripheral artery disease (PAD) than for atherosclerosis
of other territories, including coronary arteries [2]. Some of the mechanisms associated
with cigarette-smoking-induced atherogenesis include the activation of inflammation,
dysregulation of the lipid metabolism, increase in oxidative stress, and endothelial dysfunc-
tion [1,2]. Nevertheless, the pathophysiology associated with the initiation and progression
of atherosclerosis secondary to cigarette smoking is not entirely known [1,2].
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MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate the genetic
expression at the post-transcriptional level [3]. Cigarette smoking is associated with an
altered expression of circulating miRNAs, including an upregulation of pro-inflammatory
miRNAs [4,5]. On the other hand, specific miRNAs participate in different steps of athero-
genesis, and a dysregulated expression of circulating miRNAs was described in patients
with stable atherosclerosis of different territories [3,6]. However, to the best of our knowl-
edge, coexistent associations among cigarette smoking, miRNA dysregulation, and the
presence of atherosclerosis in humans have not been reported. The identification of miRNA
dysregulation in association with both cigarette smoking and atherosclerosis could provide
insights into the pathophysiology of cigarette-smoking toxicity. In fact, miRNAs may medi-
ate the causal relationship between cigarette smoking and atherosclerosis development,
especially PAD, which is particularly influenced by cigarette smoking [2].
Of the diversity of miRNAs associated with atherosclerosis regulation, miR-27b, miR-
21, miR-29a, miR-126, miR-146, and miR-218 participate in distinct pathways and/or have
distinct mechanisms of action, as described in experimental models, and were also reported
to be dysregulated in patients with stable atherosclerosis [3,6–9]. Of note, miR-27b is a
pleiotropic miRNA, and its expression is associated not only with atherosclerotic disease
but also with non-atherosclerotic cardiovascular processes, such as cardiomyocyte hyper-
trophy and non-cardiovascular diseases, including cancer, non-alcoholic fatty liver disease,
and viral infections [10–18]. Specifically, regarding atherosclerosis, miR-27b regulates lipid
metabolism, development of lipid-induced atherosclerotic lesions, vascular inflammation,
endothelial function, and angiogenesis [19–26]. Overall, the reported effects of miR-27b
in experimental models are atheroprotective [19–26]. Among the relevant roles of the
remaining miRNAs in the development and expression of atherosclerosis, miR-21 regu-
lates vascular smooth cell and endothelial cell functions, miR-29a regulates fibrosis and
extracellular matrix composition, miR-126 regulates endothelial function in response to
shear stress, miR-146 regulates endothelial function in response to inflammatory cytokines,
and miR-218 regulates endothelial cell migration [3,7,8].
We explored whether circulating miRNAs are simultaneously dysregulated in cigarette
smokers and associated with the presence of PAD.
2. Materials and Methods
The study protocol was approved by the ethics committees of the involved institu-
tions (Centro Hospitalar Universitário de Lisboa Central, Nr. 245/2015, in 2015, and the
NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de Lisboa,
Nr. 000176, in 2015). The investigation conformed to the principles outlined in the Helsinki
Declaration. All the participants signed informed consent forms.
2.1. Recruitment of Participants
Two groups of participants from our center were recruited, with and without PAD.
PAD was defined as a significant (≥50%) stenosis on Doppler ultrasound at rest [27,28]
or the combination of chronic claudication and an ankle-brachial index equal to or less
than 0.9 [28,29]. Doppler ultrasound was performed for the characterization of PAD,
according to a standardized protocol, using the GE Logiq S7 Expert Ultrasound System,
and measurements were performed while following published guidelines [28,29].
We excluded patients with critical limb ischemia (with ischemic rest pain), those with
acute ischemic events within 12 months in any arterial territory, those with lower-extremity
bypass surgery performed within 12 months, those with any prior percutaneous arterial
treatment, those with heart failure, hemodynamically significant valvular heart disease,
hematological disorders, active infection (based on symptoms and/or signs, including
fever, and leukocyte count, white blood cell differential, and C-reactive protein levels),
history of malignancy, chronic kidney disease (stage 4 or 5), or severe hepatic dysfunction,
those under 18 years of age, and those unable or unwilling to consent to study participation.
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2.2. Data Collection
Data were collected prospectively after patient inclusion. A standardized record
including clinical, demographic, laboratory, echocardiographic, and Doppler ultrasound
data was obtained from each participant. Participants were classified according to cigarette-
smoking status as never smokers, prior smokers (if cessation occurred at least six months
before), or active smokers (in cases of daily cigarette smoking, irrespective of the number
of cigarettes) [30].
2.3. Candidate miRNAs
Six candidate miRNAs (miR-21, miR-27b, miR-29a, miR-126, miR-146, and miR-218)
were selected based on the following criteria: miRNAs are associated with the regulation
of atherosclerosis development and expression in experimental models [3,7,8]; each of
the miRNAs regulates distinct pathways of atherosclerotic disease and/or has distinct
mechanisms of action [3,7,8]; miRNAs were reported to be dysregulated in patients with
stable atherosclerosis [6,9].
2.4. Quantification of Expression Levels of Candidate miRNAs
Peripheral blood was collected early in the morning under fasting conditions. Serum was
separated by centrifugation (500× g for 10 min) within 15 min of sampling. Aliquots were
stored at −80 ◦C, and samples were thawed only once.
Total RNA was extracted from serum samples using the miRCURY™ RNA Isolation
Kit (Qiagen, Hilden, Germany). Complementary DNA was synthesized from total RNA
using the Universal complementary DNA (cDNA) synthesis kit from the miRCURY™ LNA
miRNA system (Qiagen, Hilden, Germany). miRNA amplification was performed using
quantitative reverse-transcription polymerase chain reaction (using the miRCURY™ LNA
SYBR Green PCR Kit and LNA™ PCR primers, Qiagen, Hilden, Germany), and the melting
curve was determined according to the following conditions: 95 ◦C for 10 min, followed
by 45 cycles of 95 ◦C for 10 s and 60 ◦C for 60 s. All reactions were performed in triplicate.
The amplification data were assessed using DataAssist™ Software v3.01. Cycle threshold
(Ct) values greater than 40 were considered undetermined [31–34]. The relative expression
levels of the six candidate miRNAs were calculated using the delta Ct (∆Ct) method,
normalizing for the UniSp6 RNA spike-in control [34–37]. Higher ∆Ct miRs represent lower
circulating levels of the candidate miRNAs [34–37]. Where appropriate, the fold-change in
the miRNA expression levels was expressed using the Livak method (2−∆∆Ct) [38].
2.5. Statistical Analysis
Discrete variables are presented as frequencies (percentages); continuous variables
are presented as the mean (standard deviation) in normally distributed data or median
(interquartile range (IQR)) in variables without a normal distribution (Shapiro–Wilk test).
Categorical variables were analyzed using the chi-square or Fisher’s exact tests. Con-
tinuous variables were analyzed using Student’s t-test or the Mann–Whitney test when
normality was not verified. Comparisons between multiple groups were performed using
an analysis of variance (ANOVA) in normally distributed data and the Kruskal–Wallis
test in variables without a normal distribution; the Bonferroni post-hoc correction was
used for multiple pairwise comparisons. Pearson’s correlation was used to test correlations
between continuous variables. Three distinct multivariable logistic regression models
were successively tested: (1) using classical cardiovascular risk factors as the independent
variables and PAD as the dependent variable; (2) using metabolic and inflammatory data
and miRNA expression levels as the independent variables and active smoking as the
dependent variable; and (3) using miRNAs and other laboratory parameters dysregulated
in cigarette smokers as the independent variables and PAD as the dependent variable. Vari-
ables with a p-value of <0.10 in univariate analyses were tested in the multivariable models.
A correction for collinearity was performed as appropriate. The level of significance was
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set at α = 0.05. Analyses were conducted using SPSS software, version 26.0 (IBM Corp,
Armonk, NY, USA).
3. Results
3.1. Characteristics of Participants According to the Presence of PAD and
Cigarette-Smoking Status
A total of 94 participants were recruited, including 58 without and 36 with PAD
(Table 1). Patients with PAD presented a higher prevalence of classical cardiovascular risk
factors (including cigarette smoking), concomitant coronary and carotid artery disease,
and use of antiplatelet and statin therapy, as well as higher creatinine levels, compared to
patients without PAD. The ∆Ct miR-27b and ∆Ct miR-146 values were significantly higher
in patients with PAD (Table 1), corresponding to a 17.0- and 3.4-fold downregulation of
miR-27b and miR-146 [38], respectively, in patients with PAD.
Of the 94 participants, 51 were never smokers, 28 were prior smokers, and 15 were
active smokers (Table 2). The mean pack-year was 53 (22) in prior smokers and 45 (21) in
active smokers, with a median time from cigarette-smoking cessation of 10 (7–11) years
in prior smokers. The prevalence of PAD and the proportion of bilateral PAD (among
patients with PAD) increased from never smokers to prior smokers and to active smokers.
Moreover, the leukocyte, neutrophil, and lymphocyte counts were higher in active smokers
compared with other groups. MiR-27b was the only dysregulated miRNA according
to cigarette-smoking status; the ∆Ct miR-27b values were significantly higher in active
smokers compared with prior smokers (p = 0.004; corresponding to a downregulation
of miR-27b in active smokers), and there was a trend for higher ∆Ct miR-27b values in
active smokers compared with never smokers (p = 0.053; corresponding to a trend for
downregulation of miR-27b in active smokers), with no significant differences between
never smokers and prior smokers.
Active smokers presented significantly higher ∆Ct miR-27b values (22.00 (4.35)) com-
pared with non-active smokers, including never smokers and prior smokers (18.66 (4.33)),
corresponding to a 10.0-fold downregulation of miR-27b expression levels in active smok-
ers [38] (Figure 1).
3.2. Cigarette Smoking Was Independently Associated with the Presence of PAD
Considering all the risk factors for the development of cardiovascular disease that
differed according to the presence of PAD in the univariate analysis, the age, cigarette-
smoking status, and creatinine levels were independently associated with the presence of
PAD in the multivariate logistic regression analysis (Table 3).
3.3. MiR-27b Was Dysregulated in Active Smokers Independently of Other Metabolic and
Inflammatory Parameters
Considering the metabolic and inflammatory parameters and the miRNAs dysregu-
lated in active smokers in the univariate analysis, the leukocyte count and ∆Ct miR-27b
were independently associated with active smoking in the multivariate logistic regression
analysis (Table 4).
3.4. MiR-27b Was Independently Associated with the Presence of PAD
Considering all the metabolic and inflammatory parameters and the miRNA (miR-
27b) dysregulated in active smokers in the univariate analysis, only ∆Ct miR-27b was
independently associated with the presence of PAD (β = 1.13, 95% confidence interval:
1.01–1.28, p = 0.037). Moreover, ∆Ct miR-27b was significantly higher in bilateral PAD (24.0
(17.2–25.7)) compared with unilateral PAD (20.3 (15.1–23.2), p = 0.041 vs. bilateral PAD) and
with absent PAD (18.3 (14.8–21.6), p = 0.004 vs. bilateral PAD). Such results corresponded
to a 4.0- and 52.0-fold reduction in miR-27b in bilateral PAD compared with unilateral and
absent PAD, respectively [38].
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Table 1. Characteristics of participants without and with peripheral artery disease.
Characteristics of Participants Without Peripheral Artery Disease With Peripheral Artery Disease p-Value
n 58 36
Clinical characteristics
Age, years 61 (53–70) 68 (60–73) 0.009
Male, n (%) 51 (88) 33 (92) 0.419
Hypertension, n (%) 42 (72) 36 (100) <0.001
Dyslipidemia, n (%) 48 (83) 35 (97) 0.031
Diabetes mellitus, n (%) 15 (26) 17 (47) 0.029
Cigarette-smoking status, n (%) 0.001
Never smoker 39 (67) 12 (33)
Prior smoker 15 (26) 13 (36)
Active smoker 4 (7) 11 (31)
LVEF > 50%, n (%) 58 (100) 36 (100) –
Antiplatelet therapy, n (%) 37 (64) 35 (97) <0.001
Statin therapy, n (%) 42 (72) 32 (91) 0.023
Coronary artery disease, n (%) 32 (55) 36 (100) <0.001
Carotid artery disease, n (%) 12 (55) 18 (50) 0.003
Peripheral artery disease
Bilateral disease, n (%) 0 (0) 25 (69) <0.001
Prior bypass surgery, n (%) 0 (0) 8 (22) <0.001
Laboratory parameters
Hemoglobin, g/dL 13.8 (1.5) 13.6 (1.6) 0.586
Leukocyte count, 109/L 7.0 (1.9) 7.7 (1.7) 0.081
Neutrophil count, 109/L 4.0 (1.7) 4.5 (1.4) 0.192
Lymphocyte count, 109/L 1.9 (1.6–2.3) 2.2 (1.6–2.7) 0.100
Neutrophil/lymphocyte ratio 2.2 (1.0) 2.2 (1.0) 0.943
Platelet count, 109/L 223 (58) 227 (44) 0.749
Fasting glycemia, mg/dL 92 (83–104) 90 (82–121) 0.978
Percentage of glycosylated hemoglobin 5.7 (5.4–6.2) 5.9 (5.5–7.4) 0.295
Creatinine, mg/dL 0.85 (0.77–0.97) 0.94 (0.80–1.34) 0.036
Total cholesterol, mg/dL 164 (130–206) 166 (147–205) 0.781
LDL-cholesterol, mg/dL 92 (72–130) 109 (83–135) 0.250
HDL-cholesterol, mg/dL 43 (34–51) 36 (31–43) 0.062
Triglycerides, mg/dL 115 (71–163) 117 (88–178) 0.429
C-reactive protein, mg/L 4.0 (1.9) 3.6 (1.5) 0.529
miRNAs 1
miR-21 14.89 (4.51) 15.99 (4.65) 0.282
miR-27b 18.23 (14.58–21.59) 22.32 (16.50–24.13) 0.032
miR-29a 20.42 (3.57) 21.80 (3.12) 0.152
miR-126 16.89 (14.89–22.46) 19.69 (16.28–24.06) 0.060
miR-146 18.70 (3.40) 20.48 (4.23) 0.048
miR-218 22.69 (22.48–23.33) 14.49 (−8.6–23.50) 0.186
Categorical variables are expressed as the frequency (percentage), and continuous variables are expressed as the mean (standard deviation)
or median (interquartile range). HDL—high-density lipoprotein; LDL—low-density lipoprotein; LVEF—left-ventricular ejection fraction;
miRNA—microRNA. 1 Delta cycle threshold (∆Ct) values are presented for each miRNA (higher ∆Ct values correspond to lower miRNA
expression levels).
J. Clin. Med. 2021, 10, 890 6 of 13
Table 2. Characteristics of participants according to cigarette-smoking status.
Characteristics of Participants Never Smokers Prior Smokers Active Smokers p-Value
n 51 28 15
Clinical characteristics
Age, years 65 (56–73) 67 (58–71) 59 (53–68) 0.415
Male, n (%) 43 (84) 28 (100) 13 (87) 0.090
Hypertension, n (%) 36 (71) 28 (100) 14 (93) 0.002
Dyslipidemia, n (%) 43 (84) 26 (93) 14 (93) 0.424
Diabetes mellitus, n (%) 17 (33) 10 (36) 5 (33) 0.975
LVEF > 50%, n (%) 51 (100) 28 (100) 15 (100) –
Antiplatelet therapy, n (%) 36 (71) 24 (86) 12 (80) 0.298
Statin therapy, n (%) 37 (73) 24 (86) 13 (93) 0.156
Coronary artery disease, n (%) 31 (61) 24 (86) 13 (86) 0.024
Carotid artery disease, n (%) 14 (51) 10 (36) 6 (40) 0.576
Peripheral artery disease
Number of patients 12 (24) 13 (46) 11 (73) 0.001
Bilateral disease, n (%) 8 (16) 11 (39) 6 (40) 0.002
Prior bypass surgery, n (%) 2 (4) 5 (18) 1 (7) 0.101
Laboratory parameters
Hemoglobin, g/dL 13.4 (1.5) 14.1 (1.4) 14.1 (1.4) 0.063
Leukocyte count, 109/L 6.6 (1.5) 7.3 (1.8) 9.2 (1.8) <0.001 1,2
Neutrophil count, 109/L 3.8 (3.0–4.4) 3.9 (3.2–5.3) 4.6 (3.7–5.8) <0.001 1,2
Lymphocyte count, 109/L 1.8 (1.5–2.2) 2.1 (1.6–2.4) 2.3 (1.8–3.5) 0.027 1
Neutrophil/lymphocyte ratio 2.0 (1.5–3.0) 2.2 (1.7–2.7) 2.3 (1.9–2.8) 0.568
Platelet count, 109/L 219 (51) 218 (54) 255 (51) 0.058
Fasting glycemia, mg/dL 92 (83–116) 91 (85–112) 89 (72–117) 0.565
Percentage of glycosylated
hemoglobin 5.7 (5.3–7.1) 5.8 (5.4–6.2) 5.9 (5.6–6.1) 0.787
Creatinine, mg/dL 0.86 (0.78–1.08) 0.86 (0.76–1.00) 1.01 (0.75–1.71) 0.447
Total cholesterol, mg/dL 178 (51) 154 (43) 172 (48) 0.060
LDL-cholesterol, mg/dL 108 (41) 89 (38) 116 (32) 0.059
HDL-cholesterol, mg/dL 42 (34–51) 41 (29–46) 35 (31–42) 0.236
Triglycerides, mg/dL 116 (79–156) 104 (73–178) 158 (112–243) 0.139
C-reactive protein, mg/L 3.5 (1.6) 3.7 (1.8) 4.0 (1.9) 0.339
miRNAs 3
miR-21 15.44 (4.40) 14.55 (4.62) 16.42 (5.09) 0.454
miR-27b 19.29 (4.42) 17.44 (3.98) 22.00 (4.35) 0.014 2
miR-29a 21.01 (3.04) 19.74 (3.86) 23.19 (3.12) 0.059
miR-126 17.42 (15.20–23.98) 16.10 (14.89–19.48) 22.40 (17.65–24.15) 0.075
miR-146 20.03 (15.74–22.21) 17.79 (16.26–20.12) 21.69 (18.23–23.58) 0.150
miR-218 22.31 (15.67–23.02) 22.31 (15.67–23.02) 8.45 (−8.46 –21.50) 0.120
Categorical variables are expressed as the frequency (percentage), and continuous variables are expressed as the mean (standard deviation)
or median (interquartile range). HDL—high-density lipoprotein; LDL—low-density lipoprotein; LVEF—left-ventricular ejection fraction;
miRNA—microRNA. 1 p < 0.05, active smokers vs. never smokers; 2 p < 0.05, active smokers vs. prior smokers; 3 delta cycle threshold (∆Ct)
values are presented for each miRNA (higher ∆Ct values correspond to lower expression levels of candidate miRNAs).
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Creatinine, mg/dL 6.29 1.12–33.49 <0.001 
95% CI—95% confidence interval. 
3.3. MiR-27b Was Dysregulated in Active Smokers Independently of Other Metabolic and 
Inflammatory Parameters 
Considering the metabolic and inflammatory parameters and the miRNAs dysregu-
lated in active smokers in the univariate analysis, the leukocyte count and ΔCt miR-27b 
were independently associated with active smoking in the multivariate logistic regression 
analysis (Table 4). 
Table 4. Parameters dysregulated in active smokers in multivariate logistic regression analysis. 
Independent Predictors β 95% CI p-Value 
Leukocyte count 2.33 1.37–3.94 0.002 
ΔCt miR-27b 1.33 1.02–1.72 0.034 
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3.4. MiR-27b Was Independently Associated with the Presence of PAD 
Considering all the metabolic and inflammatory parameters and the miRNA (miR-
27b) dysregulated in active smokers in the univariate analysis, only ΔCt miR-27b was in-
dependently associated with the presence of PAD (β = 1.13, 95% confidence interval: 1.01–
Figure 1. Relative expression of miR-27b according to the cigarette-smoking status. The relative
expression of miR-27b (2−∆∆Ct) is presented for non-active smokers, including never smokers and
prior smokers, and for active smokers.
Table 3. Predictors of peripheral artery disease in multivariate logistic regression analysis.
Ind p ndent Predictors β 95% CI p-Value
Age, years 1.11 1.04–1.18 0.002
Cigarette sm king 4.11 1.89–8.95 0.031
Creatinine, mg/dL 6.29 1.12–33.49 <0.001
95% CI—95% confidence interval.
Table 4. Parameters dysregulated in active smokers in multivaria e logistic regression analysis.
Independent Predictors β 95% CI - alue
Leukocyte count 2.33 1.37–3.94 0.002
∆Ct miR-27b 1.33 1.02–1.72 0.034
95% CI—95% confidence interval, ∆Ct—delta cycle threshold.
4. Discussion
In this prospective study, three main findings stood out: cigarette smoking was
associated with the presence of PAD, cigarette smoking was associated with miR-27b
downregulation, and miR-27b downregulation was associated with the presence and
severity of PAD. These results suggest that miR-27b mediates the proatherogenic effects of
cigarette smoking.
Cig rette smoking is a recognized causal risk factor for PAD development [1,2]. On the
other hand, the expression of circulating miRNAs is influenced by exogenous factors,
such as cigarette smoking [4]. In this study, the atheroprotective miR-27b was downregu-
lated in active smokers compared with non-active smokers (including never smokers and
prior smokers), independently of other metabolic and inflammatory parameters. These re-
sults suggest a detrimental effect of active cigarette smoking on miR-27b expression, similar
to the reported effect of cigarette smoking on other atheroprotective miRNAs [39]. MiR-
27b was significantly downregulated in active smokers compared with prior smokers but
not with never smokers, although there was a trend towards miR-27b downregulation in
active smokers compared with never smokers. The latter may be explained by the limited
sample size used in this study. Based on an extensive post-hoc analysis, the absence of
differences in miR-27b expression levels between active smokers and never smokers is
difficult to explain, and we did not find additional factors that could contribute to such
results. Nevertheless, the numerical differences between active smokers and never smokers
were close to the margin of statistical significance and are consistent with a culprit effect
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of active smoking in downregulating miR-27b compared with prior smokers and, likely,
never smokers as well. There were no significant differences in miR-27b expression levels
between prior smokers and never smokers. Such results may be explained by a sensitivity
of miR-27b expression levels to active smoking without a legacy effect [39,40]. Specifically,
smoking cessation was reported to completely revert the dysregulation of some miRNAs
observed in active smokers [39,40], and this may also be the case of miR-27b. These data
reinforce the atheroprotective effects of smoking cessation. Published data addressing the
effect of smoking on miR-27a/b expression are limited [39–41]. Of two studies addressing
miR-27a, one reported an upregulation and the other reported no dysregulation in active
smokers [39,40]. Nevertheless, miR-27a and miR-27b may differ in their mechanisms of
action and expression levels in specific diseases, and the aforementioned results concerning
miR-27a expression in active smokers may not be applicable to miR-27b [42–44]. Specifically,
for miR-27b, a nonsignificant downregulation was reported in human oral keratinocytes
in association with cigarette smoke exposure [41]. In our study, the downregulation of
circulating miR-27b in active smokers was significant after adjusting for other metabolic
and inflammatory parameters.
The dysregulation of some circulating miRNAs is known to be associated with the
development of atherosclerosis, and miR-27b was reported to be atheroprotective on the
basis of experimental studies [19–26]. This possibly explains the association between the
reduced miR-27b expression and the higher prevalence and severity of PAD observed
in this study. Complementary atheroprotective mechanisms of miR-27b were previously
reported [19–26]. Xie W. et al. [19] elegantly showed that miR-27 reduces vascular lipid
accumulation, partially mediated by the suppression of expression of scavenger receptors
associated with lipid uptake in vascular macrophages. Interestingly, systemic treatment
with miR-27 decreased aortic plaque size and lipid content in mice [19]. Consistently,
in another study, miR-27b was identified as a crucial regulatory hub in lipid metabolism
in human and mouse liver and was shown to downregulate the expression of key genes
involved in lipid metabolism, including Angptl3 and Gpam, which mitigates the accu-
mulation of lipids in circulation [20]. Regarding inflammation, miR-27b downregulates
lipoprotein lipase gene expression and thereby reduces vascular inflammatory response,
which limits atherogenesis [19]. Moreover, miR-27b restrains the activity of NF-κB and
the production of several pro-inflammatory factors, including interleukin (IL)-1β, IL-6,
and tumor necrosis factor alpha [21], inhibits interleukin-17-induced monocyte chemoat-
tractant protein-1 [22] and targets Bcl-2-associated athanogene 2 in macrophages [21].
This contributes to a decreased monocyte-macrophage activation [23]. Considering the key
role of vascular inflammation, particularly the monocyte-macrophage activation, in the
development and expression of atherosclerosis, the aforementioned molecular mechanisms
are consistent with the atheroprotective effects of miR-27b [45,46]. On the other hand,
as miR-27b represses repulsive semaphorins, especially semaphorin 6A, it facilitates the
formation of tight endothelial monolayers and stable vessels in response to shear stress [24].
In addition, miR-27b was identified as a proangiogenic miRNA [25], regulating angio-
genesis through the angiogenic inhibitor semaphorin 6A and Notch ligand Dll4 [23,26].
Regarding studies addressing miR-27b expression in patients with PAD, data is conflicting.
Signorelli et al. [11] reported an upregulation of miR-27b in patients with PAD compared
with controls. On the other hand, Stather et al. [10] reported a downregulation of miR-
27b in patients with PAD, and our findings are consistent with their results. Contrary
to the study by Signorelli et al. [11], Stather et al. [10] confirmed the presence of PAD
using imaging methods, used one derivation and two validation sample sets, reported the
diagnostic accuracy of miR-27b for detecting PAD, and presented a pathway enrichment
analysis. There is a known biological variation in miRNAs measurements, occasionally
with conflicting expression levels among different studies focused on the same disease [47].
The miR-27b downregulation observed in our study reinforces the results of the study by
Stather et al. [10], where a very robust methodology was used.
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The downregulation of miR-27b in active smokers and the independent association
between miR-27b and the presence of PAD in this study suggest that miR-27b is down-
regulated due to active cigarette smoking and that such dysregulation contributes to PAD
(Figure 2). The results are, therefore, consistent with miR-27b acting as a mediator of
cigarette-smoking toxicity, specifically in PAD development.
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Figure 2. Putative role of miR-27b in the toxicity induced by cigarette smoking. Cigarette smoking was associated with the
presence of peripheral artery disease and with miR-27b downregulation; downregulation of the atheroprotective miR-27b
was associated with the presence and severity of peripheral artery disease; miR-27b may mediate the atherogenesis induced
by cigarette smoking. The suspension points represent metabolic and inflammatory parameters potentially dysregulated in
association with cigarette smoking, in addition to neutrophil count, lymphocyte count, and miR-27b expression.
In this study, miR-146 was also downregulated in patients with PAD. MiR-146 is
induced in endothelial cells in response to pro-inflammatory cytokines and acts as a neg-
ative feedback regulator of inflammatory signaling in endothelial cells by dampening
the activation of pro-inflammatory transcriptional programs, including the NF-κB, AP-1,
and MAPK/EGR pathways, and by promoting eNOS expression [3,7,48]. Moreover, miR-
146a was reported to decrease endothelial inflammation by inhibiting NAPDH Oxidase
4 expression in a diabetic atherothrombosis model [49]. The anti-inflammatory effects of
miR-146 contribute to counteracting atherogenesis [3,7,48,49] and may explain the associ-
ation between miR-146 downregulation and the presence of PAD observed in our study.
The remaining miRNAs (miR-21, miR-29a, miR-126, and miR-218) were not dysregulated
in association with PAD, despite their involvement in biological pathways associated with
atherosclerosis regulation, as reported in experimental studies [48,50–60]. A comprehensive
review of their biological roles is out of the scope of this study, but some of the main targets
are herein addressed. MiR-21 has both atheroprotective and proatherogenic effects [50].
It enhances vascular smooth muscle cell migration and proliferation by targeting TSP-1 and
c-Sk [50,51]. On the other hand, miR-21 inhibits both endothelial cell apoptosis, through
PTEN [52], and endothelial cell proliferation, through RhoB [53]. In addition, miR-21
promotes inflammatory activation of endothelial cells by targeting PPARα, which induces
the expression of adhesion molecules and cytokines [54]. MiR-29a acts in distinct pathways,
as it represses transcripts of several components of the extracellular matrix; of note, miR-29a
downregulates the expression of ELN, COL1A1, and COL3A1, resulting in a reduction of
the elastin and collagen content in the atherosclerotic plaque [55,56]. In fact, antagonizing
the antifibrotic effect of miR-29a leads to a reduced size of atherosclerotic lesions, enhanced
fibrous cap thickness, and reduced necrotic zones [55]. MiR-126 promotes endothelial
proliferation and limits atherosclerosis by suppressing Dlk1 [57]. Interestingly, miR-126 is
a mechanosensitive miRNA that is downregulated through the transcription factor klf2a in
response to disturbed flow and shear stress [58]. Finally, miR-218 regulates Slit/Robo sig-
naling through the repression of Robo1, Robo2, and glucuronyl C5-epimerase and thereby
regulates endothelial cell migration and vascular patterning [59,60]. As supported by the
aforementioned experimental data, further clinical studies are warranted to confirm the
role of these miRNAs as biomarkers of atherosclerosis.
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There are strengths of this study that should be acknowledged. As far as we know,
we describe for the first time coexistent associations among cigarette-smoking status,
dysregulation of circulating miR-27b, and PAD. The results were consistent with the
aforementioned biological roles of miR-27b in experimental studies [19–26]. Moreover,
the miR-27b downregulation in more severe, bilateral PAD further added to the consistency
of the results. Importantly, the multivariable analyses carried out in this study, adjusting
for confounders, contributed to the accuracy of our findings.
Our study has some limitations. The results indicate associations among cigarette
smoking, miR-27b dysregulation, and PAD development, but not a causal effect. Neverthe-
less, the adjustment for confounders in the multivariable analyses and the consistency of
the results with the aforementioned experimental data [19–26] suggest that miR-27b is very
likely a mediator in such a pathophysiology chain. Of note, this is a single-center study that
included only European participants, which may limit the applicability of results to other
clinical settings. Populations with different ethnicities may express distinct microRNA
profiles, either in healthy individuals or in specific disease subsets [61,62]. Therefore,
further multicentric studies recruiting participants from distinct geographical areas are
warranted for external validation of our findings.
5. Conclusions
Cigarette smoking was associated with the presence of PAD. Active smokers, but not
prior smokers, presented a downregulation of miR-27b, and such dysregulation was associ-
ated with the presence and severity of PAD. These unreported data suggest that miR-27b
mediates the proatherogenic effects of cigarette smoking and that cigarette smoking cessa-
tion may be associated with an attenuation of miR-27b dysregulation. Our results provide
insights into the pathophysiology of cigarette-smoking toxicity and associated PAD.
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and stroke: Meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018, 360, 5855. [CrossRef] [PubMed]
31. Deo, A.; Carlsson, J.; Lindlöf, A. How to Choose A Normalization Strategy for Mirna Quantitative Real-Time (QPCR) Arrays.
J. Bioinform. Comput. Biol. 2011, 9, 795–812. [CrossRef] [PubMed]
32. Wolfinger, R.D.; Beedanagari, S.; Boitier, E.; Chen, T.; Couttet, P.; Ellinger-Ziegelbauer, H.; Guillemain, G.; Mariet, C.; Mouritzen, P.;
O’Lone, R.; et al. Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory
biomarkers by RT-qPCR. BMC Biotechnol. 2018, 18, 6. [CrossRef]
33. Zhang, X.; Shao, S.; Geng, H.; Yu, Y.; Wang, C.; Liu, Z.; Yu, C.; Jiang, X.; Deng, Y.; Gao, L.; et al. Expression Profiles of Six
Circulating MicroRNAs Critical to Atherosclerosis in Patients With Subclinical Hypothyroidism: A Clinical Study. J. Clin.
Endocrinol. Metab. 2014, 99, 766–774. [CrossRef] [PubMed]
34. Kumar, D.; Narang, R.; Sreenivas, V.; Rastogi, V.; Bhatia, J.; Saluja, D.; Srivastava, K. Circulatory miR-133b and miR-21 as Novel
Biomarkers in Early Prediction and Diagnosis of Coronary Artery Disease. Genes 2020, 11, 164. [CrossRef]
35. Vegter, E.L.; Ovchinnikova, E.S.; Van Veldhuisen, D.J.; Jaarsma, T.; Berezikov, E.; Van Der Meer, P.; Voors, A.A. Low circulating
microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations.
Clin. Res. Cardiol. 2017, 106, 598–609. [CrossRef]
36. Stather, P.W.; Sylvius, N.; Sidloff, D.A.; Dattani, N.; Verissimo, A.; Wild, J.B.; Butt, H.Z.; Choke, E.; Sayers, R.D.; Bown, M.J.
Identification of microRNAs associated with abdominal aortic aneurysms and peripheral arterial disease. BJS 2015, 102, 755–766.
[CrossRef]
37. Huang, Y.-Q.; Ying-Ling, Z.; Chen, J.-Y.; Zhou, Y.-L.; Cai, A.-P.; Huang, C.; Feng, Y.-Q. The Association of Circulating MiR-29b
and Interleukin-6 with Subclinical Atherosclerosis. Cell. Physiol. Biochem. 2017, 44, 1537–1544. [CrossRef]
38. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−∆∆CT Method.
Methods 2001, 25, 402–408. [CrossRef]
39. Takahashi, K.; Yokota, S.-I.; Tatsumi, N.; Fukami, T.; Yokoi, T.; Nakajima, M. Cigarette smoking substantially alters plasma
microRNA profiles in healthy subjects. Toxicol. Appl. Pharmacol. 2013, 272, 154–160. [CrossRef]
40. Suzuki, K.; Yamada, H.; Nagura, A.; Ohashi, K.; Ishikawa, H.; Yamazaki, M.; Ando, Y.; Ichino, N.; Osakabe, K.; Sugimoto, K.; et al.
Association of cigarette smoking with serum microRNA expression among middle-aged Japanese adults. Fujita Med J. 2013,
2, 1–5. [CrossRef]
41. Bhat, M.Y.; Advani, J.; Rajagopalan, P.; Patel, K.; Nanjappa, V.; Solanki, H.S.; Patil, A.H.; Bhat, F.A.; Mathur, P.P.; Nair, B.; et al.
Cigarette smoke and chewing tobacco alter expression of different sets of miRNAs in oral keratinocytes. Sci. Rep. 2018, 8, 1–13.
[CrossRef]
42. Fazeli, S.; Motovali-Bashi, M.; Peymani, M.; Hashemi, M.-S.; Etemadifar, M.; Nasr-Esfahani, M.H.; Ghaedi, K. A compound
downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson’s patients is associated with
the early stage onset of disease. PLoS ONE 2020, 15, e0240855. [CrossRef]
43. Shafiei, J.; Heidari, F.; Khashen, E.; Ghandehari-Alavijeh, R.; Darmishonnejad, Z. Distinctive deregulation of miR-27a and miR-27b
in relapsing remitting multiple sclerosis. J. Bas. Res. Med. Sci. 2020, 7, 1–6.
44. Ma, M.; Yin, Z.; Zhong, H.; Liang, T.; Guo, L. Analysis of the expression, function, and evolution of miR-27 isoforms and their
responses in metabolic processes. Genomics 2019, 111, 1249–1257. [CrossRef] [PubMed]
45. Libby, P.; Ridker, P.M.; Hansson, G.K. Inflammation in Atherosclerosis. J. Am. Coll. Cardiol. 2009, 54, 2129–2138. [CrossRef]
46. Ross, R. Atherosclerosis—An Inflammatory Disease. N. Engl. J. Med. 1999, 340, 115–126. [CrossRef]
47. Kaur, A.; Mackin, S.T.; Schlosser, K.; Wong, F.L.; Elharram, M.; Delles, C.; Stewart, D.J.; Dayan, N.; Landry, T.; Pilote, L.
Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. Cardiovasc. Res.
2019, 116, 1113–1124. [CrossRef]
48. Cheng, H.S.; Sivachandran, N.; Lau, A.; Boudreau, E.; Zhao, J.L.; Baltimore, D.; Delgado-Olguin, P.; Cybulsky, M.I.; Fish, J.E.
Micro RNA -146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol. Med. 2013, 5, 1017–1034.
[CrossRef]
49. Wang, H.-J.; Huang-Joe, W.; Shih, Y.-Y.; Wu, H.-Y.; Peng, C.-T.; Lo, W.-Y. MicroRNA-146a Decreases High Glucose/Thrombin-
Induced Endothelial Inflammation by Inhibiting NAPDH Oxidase 4 Expression. Mediat. Inflamm. 2014, 2014, 1–12. [CrossRef]
[PubMed]
50. Lin, X.; Zhan, J.-K.; Wang, Y.-J.; Tan, P.; Chen, Y.-Y.; Deng, H.-Q.; Liu, Y.-S. Function, Role, and Clinical Application of MicroRNAs
in Vascular Aging. BioMed Res. Int. 2016, 2016, 1–15. [CrossRef] [PubMed]
J. Clin. Med. 2021, 10, 890 13 of 13
51. Li, J.; Zhao, L.; He, X.; Yang, T.; Yang, K. MiR-21 inhibits c-Ski signaling to promote the proliferation of rat vascular smooth
muscle cells. Cell. Signal. 2014, 26, 724–729. [CrossRef]
52. Weber, M.; Baker, M.B.; Moore, J.P.; Searles, C.D. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis
and eNOS activity. Biochem. Biophys. Res. Commun. 2010, 393, 643–648. [CrossRef]
53. Jin, C.; Zhao, Y.; Yu, L.; Xu, S.; Fu, G. MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and
migration. FEBS Lett. 2013, 587, 378–385. [CrossRef]
54. Zhou, J.; Wang, K.-C.; Wu, W.; Subramaniam, S.; Shyy, J.Y.-J.; Chiu, J.-J.; Li, J.Y.-S.; Chien, S. MicroRNA-21 targets peroxisome
proliferators-activated receptor- in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc. Natl. Acad.
Sci. USA 2011, 108, 10355–10360. [CrossRef]
55. Ulrich, V.; Rotllan, N.; Araldi, E.; Luciano, A.; Skroblin, P.; Abonnenc, M.; Perrotta, P.; Yin, X.; Bauer, A.; Leslie, K.L.; et al. Chronic
miR-29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Mol. Med. 2016, 8, 643–653. [CrossRef]
56. Zhang, P.; Huang, A.; Ferruzzi, J.; Mecham, R.P.; Starcher, B.C.; Tellides, G.; Humphrey, J.D.; Giordano, F.J.; Niklason, L.E.;
Sessa, W.C. Inhibition of MicroRNA-29 Enhances Elastin Levels in Cells Haploinsufficient for Elastin and in Bioengineered
Vessels—Brief Report. Arter. Thromb. Vasc. Biol. 2012, 32, 756–759. [CrossRef] [PubMed]
57. Schober, A.; Nazari-Jahantigh, M.; Wei, Y.; Bidzhekov, K.; Gremse, F.; Grommes, J.; Megens, R.T.A.; Heyll, K.; Noels, H.;
Hristov, M.; et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat. Med.
2014, 20, 368–376. [CrossRef]
58. Kumar, S.; Kim, C.W.; Simmons, R.D.; Jo, H. Role of Flow-Sensitive microRNAs in Endothelial Dysfunction and Atherosclerosis.
Arter. Thromb. Vasc. Biol. 2014, 34, 2206–2216. [CrossRef] [PubMed]
59. Fernández-Hernando, C.; Suárez, Y. MicroRNAs in endothelial cell homeostasis and vascular disease. Curr. Opin. Hematol. 2018,
25, 227–236. [CrossRef]
60. Small, E.M.; Sutherland, L.B.; Rajagopalan, K.N.; Wang, S.; Olson, E.N. MicroRNA-218 Regulates Vascular Patterning by
Modulation of Slit-Robo Signaling. Circ. Res. 2010, 107, 1336–1344. [CrossRef]
61. Huang, R.S.; Gamazon, E.R.; Ziliak, D.; Wen, Y.; Im, H.K.; Zhang, W.; Wing, C.; Duan, S.; Bleibel, W.K.; Cox, N.J.; et al. Population
differences in microRNA expression and biological implications. RNA Biol. 2011, 8, 692–701. [CrossRef] [PubMed]
62. Rawlings-Goss, R.A.; Campbell, M.C.; Tishkoff, S.A. Global population-specific variation in miRNA associated with cancer risk
and clinical biomarkers. BMC Med. Genom. 2014, 7, 53. [CrossRef]
